Mucosal Immunology(2011) 4, 246–251; doi:10.1038/mi.2011.11; published online 16 March 2011
The impact of mucosal infections on acquisition and progression of tuberculosis
S Perry1, R Hussain2 and J Parsonnet1
. 1Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, CA, USA
. 2Department of Molecular Biology, Aga Khan University, Karachi, Pakistan
Correspondence: S Perry, (firstname.lastname@example.org)
More than one-third of the world's population, or over 2 billion people, are infected with Mycobacterium tuberculosis, the causative pathogen of tuberculosis in humans.
Why only 10% of those infected develop active disease while the remainder harbor latent infection remains one of the greatest scientific and public health mysteries.
Bacterial persistence is characterized by a dynamic state of immunological tolerance between pathogen and host.
The critical role of CD4+ T cells in defense against intracellular pathogens became evident during epidemiological studies of HIV-1 infection, which showed a clear inverse relationship between CD4+ T-cell count in peripheral blood and increased risk of infection with M. tuberculosis, pneumocystis and Toxoplasma gondii.
There is also growing evidence of a common mucosal immune system, whereby immune cells activated at one mucosal site may disseminate to remote effector sites.
In this commentary, we review emerging evidence from human studies that the outcome of M. tuberculosis infection is influenced by concurrent mucosal infections, using Helicobacter pylori and geohelminths as examples.
Understanding how the complexity of microbial exposures influences host immunity may have important implications for vaccine development and therapeutic interventions.